#1 Clinical Trials Search in Europe

Ixekizumab

Ixekizumab, also known by its brand name Taltz, is a monoclonal antibody that targets interleukin-17A (IL-17A). This drug is being studied in clinical trials for various conditions beyond its current approved uses. These trials aim to evaluate the safety, efficacy, and potential new applications of ixekizumab in treating different diseases, ranging from rare skin conditions to mental health disorders.

Table of Contents

What is Ixekizumab?

Ixekizumab, also known by its brand name Taltz, is a prescription medication used to treat several inflammatory conditions[1]. It belongs to a class of drugs called monoclonal antibodies, which are laboratory-produced molecules designed to serve as substitute antibodies that can restore, enhance, or mimic the immune system’s attack on specific cells[2].

How Does Ixekizumab Work?

Ixekizumab works by targeting and blocking a specific protein in your body called interleukin 17A (IL-17A). This protein is involved in causing inflammation in various conditions. By inhibiting IL-17A, ixekizumab helps reduce inflammation and alleviate symptoms associated with certain inflammatory diseases[2].

Conditions Treated with Ixekizumab

Ixekizumab is approved to treat several conditions, including:

  • Plaque Psoriasis: A chronic skin condition characterized by red, scaly patches on the skin[5].
  • Psoriatic Arthritis: A type of inflammatory arthritis that affects some people with psoriasis[6].
  • Generalized Pustular Psoriasis: A rare and severe form of psoriasis characterized by widespread redness and pustules on the skin[7].
  • Erythrodermic Psoriasis: A severe form of psoriasis that affects most of the body surface[7].

Additionally, researchers are investigating its potential use in other conditions such as:

  • Idiopathic Subglottic Stenosis: A rare condition causing narrowing of the airway below the vocal cords[1].
  • Bullous Pemphigoid: An autoimmune blistering disease of the skin[2].
  • Pityriasis Rubra Pilaris: A rare inflammatory skin disease[3].
  • Treatment-Resistant Depression: A form of depression that doesn’t respond to standard treatments[8].
  • Type 1 Diabetes: An autoimmune condition affecting insulin production[9].

How is Ixekizumab Administered?

Ixekizumab is administered as a subcutaneous (under the skin) injection. The dosing schedule can vary depending on the condition being treated, but generally follows this pattern:

  • An initial higher dose (usually 160 mg) at the start of treatment.
  • Followed by regular doses (usually 80 mg) every 2 or 4 weeks, depending on the condition and treatment phase[1][4].

Your healthcare provider will determine the appropriate dosing schedule for your specific condition and needs.

Effectiveness of Ixekizumab

Clinical trials have shown ixekizumab to be effective in treating its approved conditions. For example:

  • In plaque psoriasis, many patients achieve significant improvement in skin clearance, measured by scales such as the Psoriasis Area and Severity Index (PASI)[5].
  • For psoriatic arthritis, ixekizumab has shown to improve joint symptoms and physical function[6].
  • In generalized pustular psoriasis and erythrodermic psoriasis, ixekizumab has demonstrated effectiveness in reducing disease severity[7].

Potential Side Effects

Like all medications, ixekizumab can cause side effects. Common side effects may include:

  • Injection site reactions (redness, pain, or swelling at the injection site)
  • Upper respiratory infections
  • Nausea
  • Fungal infections

More serious side effects, though rare, can occur. These may include serious allergic reactions or increased risk of infections. Always discuss potential side effects with your healthcare provider[2].

Ongoing Research and Potential New Uses

Researchers are continually exploring new potential uses for ixekizumab. Some areas of ongoing research include:

  • Idiopathic Subglottic Stenosis: Studies are investigating whether ixekizumab can reduce the need for repeated surgeries in this rare airway condition[1].
  • Bullous Pemphigoid: Research is examining if ixekizumab can effectively treat this autoimmune blistering disease[2].
  • Treatment-Resistant Depression: Scientists are exploring whether blocking IL-17A with ixekizumab could help patients with depression that hasn’t responded to other treatments[8].
  • Type 1 Diabetes: A study is investigating if ixekizumab can help preserve insulin production in newly diagnosed type 1 diabetes patients[9].

These studies highlight the potential versatility of ixekizumab in treating various inflammatory and autoimmune conditions. However, it’s important to note that these are still under investigation and not approved uses of the medication.

Condition Study Phase Key Outcomes Measured Dosing Regimen
Idiopathic Subglottic Stenosis Phase 2 Quality of life, airway function, time between surgeries 160 mg at week 0, then 80 mg every 2 weeks
Bullous Pemphigoid Not specified Blister formation, disease severity, prednisone dose 160 mg at week 0, then 80 mg every 2 weeks
Pityriasis Rubra Pilaris Not specified Clinical improvement, quality of life, itch severity 160 mg at week 0, then 80 mg every 2 weeks
Generalized Pustular Psoriasis and Erythrodermic Psoriasis Not specified Global improvement score, skin symptoms, quality of life 160 mg at week 0, then 80 mg every 2 or 4 weeks
Treatment-Resistant Depression Phase 2 Depression severity, anhedonia, suicidal ideation 160 mg at week 0, then 80 mg at weeks 2 and 4

FAQ

  • What is ixekizumab and how does it work? Ixekizumab is a monoclonal antibody that targets and blocks interleukin-17A (IL-17A), a protein involved in inflammation. By inhibiting IL-17A, ixekizumab can reduce inflammation in various conditions.
  • What conditions are being studied in clinical trials using ixekizumab? Clinical trials are exploring ixekizumab for conditions such as idiopathic subglottic stenosis, bullous pemphigoid, pityriasis rubra pilaris, generalized pustular psoriasis, erythrodermic psoriasis, and treatment-resistant depression.
  • How is ixekizumab administered in these trials? Ixekizumab is typically administered as a subcutaneous injection. The dosing regimen varies by study, but often includes an initial higher dose followed by regular maintenance doses.
  • What are some common outcomes measured in ixekizumab clinical trials? Common outcomes include changes in disease severity scores, quality of life measures, safety assessments, and in some cases, specific markers of disease activity or inflammation.
  • Are there any potential side effects of ixekizumab being monitored in these trials? Yes, the trials monitor for various side effects. Common areas of focus include injection site reactions, infections, and changes in laboratory values. The safety profile is carefully evaluated throughout the studies.

Ongoing Clinical Trials on Ixekizumab

  • Study on Proactive Drug Monitoring with Secukinumab, Ixekizumab, or Guselkumab for Patients with Moderate-to-Severe Psoriasis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study of Ixekizumab Treatment Effects on Joint and Bone Inflammation in Patients with Axial Spondyloarthritis and Psoriatic Arthritis Using Advanced Imaging Methods

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Reducing Immunosuppressive Drugs in Adults with Psoriatic Arthritis: Methotrexate Disodium, Abatacept, and Certolizumab Pegol

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy

  • Study on the Effectiveness of Ixekizumab for Patients with Refractory Psoriatic Arthritis

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Italy

  • Study on the Effectiveness of Ixekizumab and Methotrexate for Treating Dactylitis in Patients with Psoriatic Arthritis

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Ixekizumab for Rapid Pain Relief in Patients with Axial Spondyloarthritis

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study of Ixekizumab and Adalimumab for Children with Juvenile Idiopathic Arthritis, Including Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Italy The Netherlands +1

  • Study on Ixekizumab for Preserving Insulin Production in Newly Diagnosed Type 1 Diabetes Patients

    Not recruiting

    1 1
    Investigated drugs:
    Sweden

Glossary

  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Monoclonal antibodies are used to treat some types of cancer and other diseases.
  • Interleukin-17A (IL-17A): A type of protein involved in immune responses and inflammation in the body. Ixekizumab targets and blocks this protein to reduce inflammation.
  • Subcutaneous injection: A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Idiopathic subglottic stenosis: A rare condition where the airway below the vocal cords narrows for unknown reasons, causing breathing difficulties.
  • Bullous pemphigoid: An autoimmune skin disease that causes large, fluid-filled blisters on the body.
  • Pityriasis rubra pilaris: A rare skin condition characterized by reddish-orange scaly patches, thickening of the palms and soles, and hair loss.
  • Generalized pustular psoriasis: A severe form of psoriasis characterized by widespread redness and pustules on the skin.
  • Erythrodermic psoriasis: A rare and severe form of psoriasis that causes widespread, intense skin redness and shedding.
  • Treatment-resistant depression: A form of depression that doesn't respond to standard treatments, such as antidepressant medications.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • PASI (Psoriasis Area and Severity Index): A tool used to measure the severity and extent of psoriasis.
  • Quality of life measures: Assessments that evaluate how a condition or treatment affects a person's overall well-being and ability to function in daily life.

References

  1. https://clinicaltrials.gov/study/NCT05309616
  2. https://clinicaltrials.gov/study/NCT03099538
  3. https://clinicaltrials.gov/study/NCT03485976
  4. https://clinicaltrials.gov/study/NCT03073213
  5. https://clinicaltrials.gov/study/NCT02387801
  6. https://clinicaltrials.gov/study/NCT05855967
  7. https://clinicaltrials.gov/study/NCT03942042
  8. https://clinicaltrials.gov/study/NCT04979910
  9. https://clinicaltrials.eu/trial/study-on-ixekizumab-for-preserving-insulin-production-in-newly-diagnosed-type-1-diabetes-patients/